292 related articles for article (PubMed ID: 34587768)
1. Biologic Use in Pediatric Patients With Hidradenitis Suppurativa: A Systematic Review.
Sachdeva M; Kim P; Mufti A; Maliyar K; Sibbald C; Alavi A
J Cutan Med Surg; 2022; 26(2):176-180. PubMed ID: 34587768
[TBL] [Abstract][Full Text] [Related]
2. Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar.
Lovrić I; Brkić J; Ćorluka M; Čović M; Pejić J; Zeljko Penavić J
Acta Dermatovenerol Croat; 2021 Jul; 29(2):108-110. PubMed ID: 34477078
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal observational study of hidradenitis suppurativa: impact of surgical intervention with adjunctive biologic therapy.
Shanmugam VK; Mulani S; McNish S; Harris S; Buescher T; Amdur R
Int J Dermatol; 2018 Jan; 57(1):62-69. PubMed ID: 29130482
[TBL] [Abstract][Full Text] [Related]
4. Drug Survival of Biologics in Patients With Hidradenitis Suppurativa.
Ring HC; Maul JT; Yao Y; Wu JJ; Thyssen JP; Thomsen SF; Egeberg A
JAMA Dermatol; 2022 Feb; 158(2):184-188. PubMed ID: 34851360
[TBL] [Abstract][Full Text] [Related]
5. A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs.
Holcomb ZE; Porter ML; Kimball AB
Expert Opin Drug Saf; 2021 Oct; 20(10):1147-1161. PubMed ID: 33910441
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Characteristics and Trends in Treatment Response of Hidradenitis Suppurativa Patients: A Southern US Cohort Study.
Peterson GC; Preston A; Frieder J; Wang X; Paek SY
Dermatology; 2020; 236(5):413-420. PubMed ID: 31935718
[TBL] [Abstract][Full Text] [Related]
7. Paradoxical Hidradenitis Suppurativa in Patients Receiving TNF-α Inhibitors: Case Series, Systematic Review, and Case Meta-Analysis.
Salvador-Rodriguez L; Montero-Vílchez T; Arias-Santiago S; Molina-Leyva A
Dermatology; 2020; 236(4):307-313. PubMed ID: 32135533
[TBL] [Abstract][Full Text] [Related]
8. Treatment of hidradenitis suppurativa with biologic medications.
Lee RA; Eisen DB
J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S82-8. PubMed ID: 26470624
[TBL] [Abstract][Full Text] [Related]
9. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study.
Rivera-Díaz R; Pozo T; Alfageme F; Díaz Ley B; Osorio GF; Chico R; Vilarrasa E; Silvente C; Ciudad Blanco C; Romaní J; Martorell A; Fernández P; Romero Ferreiro C; Molina Leyva A
Actas Dermosifiliogr; 2023 Oct; 114(9):755-762. PubMed ID: 37331620
[TBL] [Abstract][Full Text] [Related]
10. Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials.
Maarouf M; Clark AK; Lee DE; Shi VY
J Dermatolog Treat; 2018 Aug; 29(5):441-449. PubMed ID: 29098911
[TBL] [Abstract][Full Text] [Related]
11. Metabolic, pharmacokinetic, and toxicological issues of biologic therapies currently used in the treatment of hidradenitis suppurativa.
Molinelli E; Sapigni C; Campanati A; Brisigotti V; Offidani A
Expert Opin Drug Metab Toxicol; 2020 Nov; 16(11):1019-1037. PubMed ID: 32896186
[TBL] [Abstract][Full Text] [Related]
12. Hidradenitis suppurativa (HS): An unrecognized paradoxical effect of biologic agents (BA) used in chronic inflammatory diseases.
Faivre C; Villani AP; Aubin F; Lipsker D; Bottaro M; Cohen JD; Durupt F; Jeudy G; Sbidian E; Toussirot E; Badot V; Barbarot S; Debarbieux S; Delaporte E; Goegebeur G; Morel J; Nassif A; Duru G; Jullien D;
J Am Acad Dermatol; 2016 Jun; 74(6):1153-9. PubMed ID: 26965410
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab-Induced Paradoxical Psoriasis Treated with Biologics Targeting the IL-17/IL-23 Axis in Patients with Hidradenitis Suppurativa.
Tsiogka A; Liakou AI; Agiasofitou E; Gregoriou S; Stratigos A; Rigopoulos D; Kontochristopoulos G
Dermatology; 2023; 239(6):937-941. PubMed ID: 37579735
[TBL] [Abstract][Full Text] [Related]
14. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study.
Rivera-Díaz R; Pozo T; Alfageme F; Díaz Ley B; Osorio GF; Chico R; Vilarrasa E; Silvente C; Ciudad Blanco C; Romaní J; Martorell A; Fernández P; Romero Ferreiro C; Molina Leyva A
Actas Dermosifiliogr; 2023 Oct; 114(9):T755-T762. PubMed ID: 37479135
[TBL] [Abstract][Full Text] [Related]
15. Biologics for hidradenitis suppurativa: an update.
Włodarek K; Ponikowska M; Matusiak Ł; Szepietowski JC
Immunotherapy; 2019 Jan; 11(1):45-59. PubMed ID: 30702012
[TBL] [Abstract][Full Text] [Related]
16. LOSS OF EFFICACY OF ADALIMUMAB IN HIDRADENITIS SUPPURATIVA: FOCUS ON ALTERNATIVES.
Tchernev G
Georgian Med News; 2023; (340-341):297-300. PubMed ID: 37805915
[TBL] [Abstract][Full Text] [Related]
17. Overview and update on biologic therapy for moderate-to-severe hidradenitis suppurativa.
Porter ML; Golbari NM; Lockwood SJ; Kimball AB
Semin Cutan Med Surg; 2018 Sep; 37(3):182-189. PubMed ID: 30215636
[TBL] [Abstract][Full Text] [Related]
18. Treatment of hidradenitis suppurativa with tumour necrosis factor-alpha inhibitors.
Haslund P; Lee RA; Jemec GB
Acta Derm Venereol; 2009 Nov; 89(6):595-600. PubMed ID: 19997689
[TBL] [Abstract][Full Text] [Related]
19. Ustekinumab treatment for hidradenitis suppurativa.
Takeda K; Kikuchi K; Kanazawa Y; Yamasaki K; Aiba S
J Dermatol; 2019 Dec; 46(12):1215-1218. PubMed ID: 31638283
[TBL] [Abstract][Full Text] [Related]
20. Biology of Interleukin-17 and Novel Therapies for Hidradenitis Suppurativa.
Sabat R; Gudjonsson JE; Brembilla NC; van Straalen KR; Wolk K
J Interferon Cytokine Res; 2023 Dec; 43(12):544-556. PubMed ID: 37824200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]